Anavex Life Sciences Corp (AVXL)

[falconer66a]

Globally, $95,000,000,000,000 investment dollars available for AVXLs.

SAVA is only a threat to its stockholders. It is no threat to AVXL.

To presume, as others here have, that SAVA (Cassava Sciences, Inc.) is, somehow, an exclusionary competitor to AVXL (Anavex Life Sciences Corp) is plainly foolish. Such a stance presumes that in all of the equity-investing world there is a limited number of dollars available to buy biotech equities. If lots of of the biotech equity dollars buy up SAVAs, there will be fewer to buy up AVXLs.

Foolish, on the face of it. One source states that, globally, $95,000,000,000,000 ($95 trillion) are invested in equities. To think that there won’t be lots of new buyers of AVXL shares, buying lots of shares at rapidly ascending prices when blarcamesine gets FDA approval is ignorant.

The share prices of any other biotech or pharmaceutical are irrelevant to and has no real effect on the share price of AVXL. Innumerable dollars to go around. The only thing that, in the end, will count is clinical efficacy. With the three clinical trials coming to an end, Anavex will have that, next year.